LOS ANGELES, CA / ACCESSWIRE / May 23, 2018 / Pediapharm Inc. (the "Company" or "Pediapharm") (TSX-V: PDP) (OTCQB: PDDPF), Canada's Leading Pediatric Pharmaceutical Company, today announced that it will be presenting at the 8th annual LD Micro Invitational on Tuesday, June 5 at 11:00AM PST. Sylvain Chretien, CEO of Pediapharm, will be giving the presentation and meeting with investors.
"The event is slated to be our largest Invitational to date." stated Chris Lahiji, President of LD Micro. "When the fires caused the cancellation of our Main Event back in December, we vowed to come back even stronger. This event showcases our firm's ability to attract the most unique and exciting names in micro-cap."
The conference will be held at the Luxe Sunset Bel Air Hotel, will feature 230 companies in the small-cap / micro-cap space, and will be attended by over 1,000 individuals.
View Pediapharm's profile here: https://www.ldmicro.com/profile/PDP.V.
Profiles powered by LD Micro - News Compliments of ACCESSWIRE.
About Pediapharm
Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The Company's innovative product portfolio includes NYDA®, a breakthrough treatment for head lice; Relaxa™, an osmotic laxative used to treat constipation; EpiCeram®, a non-steroid emulsion for eczema; naproxen suspension, indicated to treat pain and inflammation due to various conditions, including Juvenile Idiopathic Arthritis; Rupall™, an innovative new allergy medication with a unique mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for chronic severe drooling, a condition affecting a significant proportion of cerebral palsy patients.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The firm hosts several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.
For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.
Contact:
Name: Roland Boivin
Phone: 514-762-2626 X202
Address: 225 – 1 Place du Commerce, Verdun, QC, Canada, H3E 1A2
Email: roland.boivin@pedia-pharm.com
Or
Name: Frank Candido
Phone: 514-969-5530
Email: frank.candido@pedia-pharm.com
SOURCE: Pediapharm
